Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director | 662k | -- | 1975 |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board | -- | -- | 1972 |
| Mr. Robert Hendriks | Senior VP of Finance | -- | -- | -- |
| Mr. Alexander Zurcher | COO & Member of Management Board | -- | -- | 1975 |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board | -- | -- | 1970 |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology | -- | -- | -- |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | -- | -- | -- |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development | -- | -- | -- |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant | -- | -- | 1956 |
| Ms. Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development | -- | -- | -- |
Molecular Partners AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 167
Description
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Corporate Governance
Upcoming Events
March 7, 2025 at 10:59 AM UTC
Molecular Partners AG Earnings Date
Recent Events
Recent Events Information Not Available